NAS:SGMT (USA)
Â
Ordinary Shares - Series A
$
2.07
-0.19 (-8.37%)
11:08 PM EST
Warning! GuruFocus detected
1 Severe warning sign
with SGMT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Sagimet Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US7867001049
Share Class Description:
SGMT: Ordinary Shares - Series ACompare
Compare
Traded in other countries / regions
SGMT.USA0O2.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2023-07-14Description
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1939.1 | |||||
| Equity-to-Asset | 0.97 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -17.5 | |||||
| 3-Year EPS without NRI Growth Rate | -10.7 | |||||
| 3-Year FCF Growth Rate | -11.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -46.86 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 4.83 | |||||
| 9-Day RSI | 12.88 | |||||
| 14-Day RSI | 20.46 | |||||
| 3-1 Month Momentum % | -29.58 | |||||
| 6-1 Month Momentum % | -14.43 | |||||
| 12-1 Month Momentum % | -35.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 34.3 | |||||
| Quick Ratio | 34.3 | |||||
| Cash Ratio | 33.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.2 | |||||
| Shareholder Yield % | -158.64 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -28.81 | |||||
| ROA % | -27.94 | |||||
| ROIC % | -558.41 | |||||
| 3-Year ROIIC % | -446.08 | |||||
| ROC (Joel Greenblatt) % | -23073.73 | |||||
| ROCE % | -34.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.43 | |||||
| EV-to-EBIT | 1.55 | |||||
| EV-to-Forward-EBIT | -0.26 | |||||
| EV-to-EBITDA | 1.55 | |||||
| EV-to-Forward-EBITDA | -0.27 | |||||
| EV-to-Forward-Revenue | 2.37 | |||||
| EV-to-FCF | 1.99 | |||||
| Price-to-Net-Current-Asset-Value | 0.45 | |||||
| Price-to-Net-Cash | 0.45 | |||||
| Earnings Yield (Greenblatt) % | 64.52 | |||||
| FCF Yield % | -63.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SGMT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sagimet Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.43 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 114.01 | ||
| 14-Day RSI | 20.46 | ||
| 14-Day ATR ($) | 0.31789 | ||
| 20-Day SMA ($) | 3.47475 | ||
| 12-1 Month Momentum % | -35.78 | ||
| 52-Week Range ($) | 2.03 - 7.38 | ||
| Shares Outstanding (Mil) | 32.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sagimet Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sagimet Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sagimet Biosciences Inc Frequently Asked Questions
What is Sagimet Biosciences Inc(SGMT)'s stock price today?
The current price of SGMT is $2.07. The 52 week high of SGMT is $7.38 and 52 week low is $2.03.
When is next earnings date of Sagimet Biosciences Inc(SGMT)?
The next earnings date of Sagimet Biosciences Inc(SGMT) is 2025-05-15 Est..
Does Sagimet Biosciences Inc(SGMT) pay dividends? If so, how much?
Sagimet Biosciences Inc(SGMT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers